ACC: Discontinuing β-Blockers Noninferior for Stabilized Acute MI

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Carmen Pope, BPharm. Last updated on April 2, 2026.

via HealthDay

THUSDAY, April 2, 2026 -- For stabilized acute myocardial infarction (AMI) without left ventricular systolic dysfunction or heart failure, discontinuing β-blockers after one year or longer is noninferior to continuing β-blockers, according to a study published online March 30 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Cardiology, held from March 28 to 30 in New Orleans.

Ki Hong Choi, M.D., from Samsung Medical Center in Seoul, South Korea, and colleagues examined the long-term benefits of β-blocker therapy in stabilized patients with AMI without left ventricular systolic dysfunction or history of heart failure in a randomized, noninferiority trial. Stabilized patients with AMI who had received β-blocker therapy for one year or longer were randomly assigned to either discontinue or continue β-blocker therapy (1,246 and 1,294 individuals, respectively).

The researchers found that a primary end point event (composite of all-cause death, recurrent MI, or hospitalization for heart failure) occurred in 58 and 74 patients in the discontinuation and continuation groups, respectively, after a median follow-up of 3.1 years (four-year Kaplan-Meier estimate, 7.2 versus 9.0 percent; hazard ratio, 0.80; 95 percent confidence interval, 0.57 to 1.13; P = 0.001 for noninferiority). The two groups had a similar incidence of serious adverse events.

"In practice, for stable patients who are several years out from a heart attack, discontinuation can be considered through shared decision-making and with monitoring of blood pressure and heart rate," senior author Joo-Yong Hahn, M.D., also from Samsung Medical Center, said in a statement.

Several authors disclosed ties to the biopharmaceutical and health technology industries.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-03 01:52

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords